Adoption and Implementation of Medications in Addiction Treatment Programs

Overview

Journal J Addict Med

Specialty Psychiatry

Date 2011 Mar 2

PMID 21359109

Citations 108

Authors

Hannah K Knudsen

Amanda J Abraham

Paul M Roman

Affiliations

Soon will be listed here.

Abstract

Objectives: Little is known about the extent to which medications are being implemented as routine care in addiction treatment programs. This research describes medication adoption and implementation within the privately funded treatment sector.

Methods: Face-to-face interviews were conducted with 345 administrators of a nationally representative sample of privately funded substance treatment organizations in the United States.

Results: Rates of adoption of addiction treatment medications in private sector programs were lower than the adoption of psychiatric medications. Even when analyses were restricted to programs with access to physicians, adoption of each addiction treatment medication had occurred in less than 50% of programs. Within adopting programs, implementation was highly variable. While about 70% of patients with co-occurring psychiatric diagnoses received psychiatric medications, rates of implementation of medication-assisted treatment for opioid dependence and alcohol use disorders were just 34.4% and 24.0%, respectively.

Conclusions: Although previous research has documented higher rates of medication adoption in privately funded treatment programs, this study revealed that both adoption and implementation of pharmacotherapies to treat addiction remains modest. Future research should examine the different types of barriers to implementation, such as physician decision-making, patient preferences, and system-level barriers stemming from financing and public policy.

Citing Articles

A Survey of Medication Diffusion and Attitudes Among Indian Clinicians Toward Pharmacotherapies for Alcohol Use Disorder.

Ghosh S, Modak T, Rozatkar A Indian J Psychol Med. 2024; 46(6):544-551.

PMID: 39545105 PMC: 11558721. DOI: 10.1177/02537176241229197.

Simulating the effects of medicaid expansion on the opioid epidemic in North Carolina.

Berghammer A, Adams J, Khan S, Bobashev G Drug Alcohol Depend Rep. 2024; 12:100262.

PMID: 39139778 PMC: 11320412. DOI: 10.1016/j.dadr.2024.100262.

Prevalence and predictors of medication for opioid use disorder among reproductive-aged women.

Bello J, Dell N, Laxton A, Conte M, Chen L Drug Alcohol Depend Rep. 2024; 11:100239.

PMID: 38711835 PMC: 11070671. DOI: 10.1016/j.dadr.2024.100239.

When a pandemic and epidemic collide: Lessons learned about how system barriers can interrupt implementation of addiction research.

Sharp A, Carlson M, Vroom E, Rigg K, Hills H, Harding C Implement Res Pract. 2023; 4:26334895231205890.

PMID: 37936966 PMC: 10572032. DOI: 10.1177/26334895231205890.

Prevention and Intervention with Young People as a Critical Public Health Strategy to Curtail the Opioid Epidemic: A Call to Action.

Danielson C, McCauley J, Hinkley J, Hahn A, Moreland A, Lopez C J Addict Res Ther. 2023; 14(4).

PMID: 37539047 PMC: 10399295.

References

Roman P, Johnson J . Adoption and implementation of new technologies in substance abuse treatment. J Subst Abuse Treat. 2002; 22(4):211-8. DOI: 10.1016/s0740-5472(02)00241-6. View

Fitzgerald J, McCarty D . Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach. Psychol Serv. 2010; 6(1):74-84. PMC: 2855198. DOI: 10.1037/a0013420. View

Abraham A, Ducharme L, Roman P . Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs. 2009; 70(4):628-35. PMC: 2696303. DOI: 10.15288/jsad.2009.70.628. View

Ducharme L, Knudsen H, Roman P, Johnson J . Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat. 2007; 32(4):321-9. PMC: 2365704. DOI: 10.1016/j.jsat.2006.05.021. View

Kissin W, McLeod C, Sonnefeld J, Stanton A . Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis. 2006; 25(4):91-103. DOI: 10.1300/J069v25n04_09. View

Koch A, Arfken C, Schuster C . Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend. 2006; 83(3):274-8. DOI: 10.1016/j.drugalcdep.2005.12.005. View

Netherland J, Botsko M, Egan J, Saxon A, Cunningham C, Finkelstein R . Factors affecting willingness to provide buprenorphine treatment. J Subst Abuse Treat. 2008; 36(3):244-51. PMC: 2866292. DOI: 10.1016/j.jsat.2008.06.006. View

Knudsen H, Ducharme L, Roman P . The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend. 2006; 87(2-3):164-74. PMC: 1868517. DOI: 10.1016/j.drugalcdep.2006.08.013. View

Reif S, Thomas C, Wallack S . Factors determining how early adopter physicians use buprenorphine in treatment. J Addict Med. 2011; 1(4):205-12. DOI: 10.1097/ADM.0b013e31814c3fa8. View

10.

Heinrich C, Hill C . Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res. 2008; 43(3):951-70. PMC: 2442246. DOI: 10.1111/j.1475-6773.2007.00812.x. View

11.

Knudsen H, Roman P . Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. J Subst Abuse Treat. 2003; 26(1):353-61. DOI: 10.1016/s0740-5472(03)00158-2. View

12.

Knudsen H, Abraham A, Johnson J, Roman P . Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009; 37(3):307-12. PMC: 2746383. DOI: 10.1016/j.jsat.2008.12.004. View

13.

Friedmann P, Jiang L, Alexander J . Top manager effects on buprenorphine adoption in outpatient substance abuse treatment programs. J Behav Health Serv Res. 2009; 37(3):322-37. PMC: 3682405. DOI: 10.1007/s11414-009-9169-z. View

14.

Knudsen H, Ducharme L, Roman P, Link T . Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat. 2005; 29(2):95-106. DOI: 10.1016/j.jsat.2005.05.002. View

15.

Knudsen H, Ducharme L, Roman P . The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment. J Health Soc Behav. 2007; 48(2):195-210. DOI: 10.1177/002214650704800207. View

16.

Wallack S, Thomas C, Martin T, Chilingerian J, Reif S . Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication. J Behav Health Serv Res. 2008; 37(1):64-78. DOI: 10.1007/s11414-008-9132-4. View

17.

Horgan C, Reif S, Hodgkin D, Garnick D, Merrick E . Availability of addiction medications in private health plans. J Subst Abuse Treat. 2007; 34(2):147-56. PMC: 2347353. DOI: 10.1016/j.jsat.2007.02.004. View

18.

Mark T, Kranzler H, Song X . Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003; 71(3):219-28. DOI: 10.1016/s0376-8716(03)00134-0. View

19.

Rieckmann T, Daley M, Fuller B, Thomas C, McCarty D . Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007; 32(2):207-15. PMC: 2847884. DOI: 10.1016/j.jsat.2006.09.002. View

20.

Mark T, Swait J . Using stated preference modeling to forecast the effect of medication attributes on prescriptions of alcoholism medications. Value Health. 2003; 6(4):474-82. DOI: 10.1046/j.1524-4733.2003.64247.x. View